ReP USP - Resultado da busca

Artigo de periodico
Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension (2019)
Torbicki, Adam; Bacchi, Marisa; Delcroix, Marion; Farber, Harrison W; Ghofrani, Hossein-Ardeschir; Hennessy, Brian; Jansa, Pavel; Mehta, Sanjay; Perchenet, Loic; Souza, Rogério
Source: Circulation-cardiovascular quality and outcomes. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, DOENÇAS RARAS, SOBREVIDA, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TORBICKI, Adam et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension. Circulation-cardiovascular quality and outcomes, v. 12, n. 5, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCOUTCOMES.118.005095. Acesso em: 04 nov. 2024.
APA
Torbicki, A., Bacchi, M., Delcroix, M., Farber, H. W., Ghofrani, H. -A., Hennessy, B., et al. (2019). Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension. Circulation-cardiovascular quality and outcomes, 12( 5). doi:10.1161/CIRCOUTCOMES.118.005095
NLM
Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani H-A, Hennessy B, Jansa P, Mehta S, Perchenet L, Souza R. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension [Internet]. Circulation-cardiovascular quality and outcomes. 2019 ; 12( 5):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1161/CIRCOUTCOMES.118.005095
Vancouver
Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani H-A, Hennessy B, Jansa P, Mehta S, Perchenet L, Souza R. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension [Internet]. Circulation-cardiovascular quality and outcomes. 2019 ; 12( 5):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1161/CIRCOUTCOMES.118.005095
Artigo de periodico
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (2017)
Mehta, Sanjay; Sastry, Bhagavatula Kutumba Srinivasa; Souza, Rogério; Torbicki, Adam; Ghofrani, Hossein-Ardeschir; Channick, Richard N.; Delcroix, Marion; Pulido, Tomás; Simonneau, Gérald; Wlodarczyk, John; Rubin, Lewis J.; Jansa, Pavel; Hunsche, Elke; Galiè, Nazzareno; Perchenet, Loïc; Sitbon, Olivier
Source: CHEST. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, QUALIDADE DE VIDA, FARMACOTERAPIA, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEHTA, Sanjay et al. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, v. 151, n. 1, p. 106-118, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.chest.2016.08.1473. Acesso em: 04 nov. 2024.
APA
Mehta, S., Sastry, B. K. S., Souza, R., Torbicki, A., Ghofrani, H. -A., Channick, R. N., et al. (2017). Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, 151( 1), 106-118. doi:10.1016/j.chest.2016.08.1473
NLM
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Vancouver
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Artigo de periodico
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017)
Galiè, Nazzareno; Jansa, Pavel; Pulido, Tomás; Channick Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loïc; Rubin Lewis J.; Sastry, B.K.S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam
Source: European Heart Journal. Unidade: FM
Subjects: MORTALIDADE, CATETERISMO CARDÍACO, ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GALIÈ, Nazzareno et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, v. 38, n. 15, p. 1147-1155, 2017Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehx025. Acesso em: 04 nov. 2024.
APA
Galiè, N., Jansa, P., Pulido, T., Channick Richard N.,, Delcroix, M., Ghofrani, H. -A., et al. (2017). SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 38( 15), 1147-1155. doi:10.1093/eurheartj/ehx025
NLM
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Vancouver
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Artigo de periodico
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN (2015)
Simonneau, Gérald; Channick, Richard N.; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loic; Pulido, Tomás; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Rubin, Lewis J.
Source: European respiratory journal. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, ESTUDOS DE COORTES, FÁRMACOS (SISTEMA RESPIRATÓRIO), ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SIMONNEAU, Gérald et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European respiratory journal, v. 46, n. 6, p. 1711-1720, 2015Tradução . . Disponível em: https://doi.org/10.1183/13993003.00364-2015. Acesso em: 04 nov. 2024.
APA
Simonneau, G., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. -A., Jansa, P., et al. (2015). Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European respiratory journal, 46( 6), 1711-1720. doi:10.1183/13993003.00364-2015
NLM
Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Souza R, Torbicki A, Rubin LJ. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN [Internet]. European respiratory journal. 2015 ; 46( 6): 1711-1720.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1183/13993003.00364-2015
Vancouver
Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Souza R, Torbicki A, Rubin LJ. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN [Internet]. European respiratory journal. 2015 ; 46( 6): 1711-1720.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1183/13993003.00364-2015
Artigo de periodico
Effect of macitentan on hospitalizations: Results from the SERAPHIN trial (2015)
Channick, Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Hunsche, Elke; Jansa, Pavel; Le Brun, Franck-Olivier; Mehta, Sanjay; Pulido, Tomás; Rubin, Lewis J.; Sastry, B. K. S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério de; Torbicki, Adam; Galiè, Nazzareno
Source: JACC Heart failure. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, FÁRMACOS/SISTEMA RESPIRATÓRIO, HOSPITALIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHANNICK, Richard N. et al. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. JACC Heart failure, v. 3, n. 1, p. 1-8, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2014.07.013. Acesso em: 04 nov. 2024.
APA
Channick, R. N., Delcroix, M., Ghofrani, H. -A., Hunsche, E., Jansa, P., Le Brun, F. -O., et al. (2015). Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. JACC Heart failure, 3( 1), 1-8. doi:10.1016/j.jchf.2014.07.013
NLM
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R de, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial [Internet]. JACC Heart failure. 2015 ; 3( 1): 1-8.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1016/j.jchf.2014.07.013
Vancouver
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R de, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial [Internet]. JACC Heart failure. 2015 ; 3( 1): 1-8.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1016/j.jchf.2014.07.013
Artigo de periodico
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension (2013)
Pulido, Tomás; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loïc; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gérald
Source: The New England Journal of Medicine. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR (MORTALIDADE), CATETERISMO CARDÍACO, CONDUTAS TERAPÊUTICAS, MEDICAMENTO (EFEITOS ADVERSOS), MÉTODO DUPLO-CEGO, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PULIDO, Tomás et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, v. 369, n. 9, p. 809-818, 2013Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917. Acesso em: 04 nov. 2024.
APA
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. -A., et al. (2013). Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, 369( 9), 809-818. doi:10.1056/NEJMoa1213917
NLM
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2024 nov. 04 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917
Vancouver
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2024 nov. 04 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Indexado em

Non normalized affiliation

Countries of institutions of collaboration